Buprenorphine and Toremifene: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Toremifene
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can affect your heart's rhythm. Buprenorphine (a pain or addiction medicine) and toremifene (a breast cancer medicine) can each stretch out a part of your heartbeat called the QT interval. When you take them together, that effect can add up, which in rare cases can lead to an irregular heartbeat.
The good news is that this is a possible risk based on how these drugs work, not something guaranteed to happen. Your care team can watch for it, check your heart tracing (ECG), and keep an eye on things like your potassium and magnesium levels. Please don't stop either medicine on your own. Just let your doctor or pharmacist know you take both so they can keep you safe.
Effect: Additive QT interval prolongation with concurrent buprenorphine and toremifene. Both agents independently prolong the QT interval, so combined use raises torsades de pointes risk (pharmacodynamic, additive; neither is a prodrug relevant here).
- Direction/magnitude: Increased QT effect; quantitative magnitude unknown.
- Onset: Unspecified.
- Evidence: Theoretical.
- Management: Avoid concomitant use where possible. If co-prescribed, obtain baseline and follow-up ECGs, correct and monitor electrolytes (K+, Mg2+), and assess additional risk factors (bradycardia, CHF, congenital long-QT, digitalis therapy, recent AF conversion). Dose and monitoring should be individualized by the care team.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
The simultaneous administration of buprenorphine alongside medications capable of prolonging the QT interval should be avoided342. It remains unknown what risk arises from pairing buprenorphine with additional agents that prolong QT prolongation. When buprenorphine is prescribed to patients who carry risk factors, including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia, these considerations should inform clinical decisions 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. Because this combination may add to QT prolongation, your team will decide how best to manage it.
- Where possible, prescribers try to avoid using these two together, or may consider an alternative.
- If you need both, your team may monitor you more closely with ECGs and check your potassium and magnesium levels.
- Tell your doctor about heart rhythm problems, fainting, dizziness, palpitations, congestive heart failure, or other QT-affecting medicines.
- Ask your pharmacist before adding any new prescription or over-the-counter product.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Toremifene together?
Buprenorphine and toremifene can each prolong the QT interval, and together the risk may add up, so prescribers generally try to avoid combining them; if you take both, let your care team monitor your heart and electrolytes. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Toremifene interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Toremifene interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. Because this combination may add to QT prolongation, your team will decide how best to manage it. Where possible, prescribers try to avoid using these two together, or may consider an alternative. If you need both, your team may monitor you more closely with ECGs and check your potassium and magnesium levels. Tell… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Toremifene need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Toremifene
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist